R&D News | pharmaphorum

News

Amgen splashes out on ChemoCentryx and its blockbuster hopef...

Ten months after ChemoCentryx scored an unexpected FDA approval for autoimmune disease therapy Tavneos, Amgen has swooped in with a $3.7 billion bid to buy out the company.

News

Pfizer takes pipeline blow as it abandons cardiomyopathy dru...

Pfizer has stopped development of a drug to treat cardiomyopathy caused by a rare form of heart disease, after it proved ineffective in a phase 3 trial.

News

Keytruda fluffs its lines in prostate, liver cancer trials

Two phase 3 trials of Merck & Co's Keytruda in metastatic castration-resistant prostate cancer (CRPC) and advanced liver cancer have ended in failure, proving once again that cancer imm

News

Chinese biotech Sironax raises $200m for RIPK1 pipeline

Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire to back companies working on RIPK1 inhibitors despite setbacks for

News

Phase 3 lung cancer fail dents prospects of Ipsen, Servier's...

Ipsen and Servier's hopes of extending the uses for chemotherapy drug Onivyde have been knocked back by a failed phase 3 trial of the drug as a second-line therapy for small cell lung cance

News

Roche adds to pipeline with Poseida, Kiniksa deals

Roche has announced a pair of licensing deals with Poseida Therapeutics and Kiniksa Pharmaceuticals that bolster its pipeline in cancer and inflammatory diseases.

Amgen splashes out on ChemoCentryx and its blockbuster hopef...

Pfizer takes pipeline blow as it abandons cardiomyopathy dru...

Keytruda fluffs its lines in prostate, liver cancer trials

Chinese biotech Sironax raises $200m for RIPK1 pipeline

Phase 3 lung cancer fail dents prospects of Ipsen, Servier's...

Roche adds to pipeline with Poseida, Kiniksa deals

Five indications added to Pharmacy First prescribing scheme

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks